Dogwood Therapeutics, Inc. (DWTX): Cash & Equivalents
$6.52M
As of 2025-12-31
$9.61M
As of 2026-06-30
-2.5%
3-year compound annual growth
-26.2%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $6.52M | -56.1% | 2026-03-18, Balance as of period end |
| 2024-12-31 | $14.85M | +347.6% | 2026-03-18, Balance as of period end |
| 2023-12-31 | $3.32M | -52.8% | 2025-03-31, Balance as of period end |
| 2022-12-31 | $7.03M | -49.8% | 2024-03-08, Balance as of period end |
| 2021-12-31 | $14.01M | -53.0% | 2023-03-14, Balance as of period end |
| 2020-12-31 | $29.80M | n/a | 2022-03-18, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Dogwood Therapeutics, Inc. (DWTX) | 2025-12-31 | $6.52M | -56.1% |
| vTv Therapeutics Inc. (VTVT) | 2025-12-31 | $88.93M | +142.0% |
| Shattuck Labs, Inc. (STTK) | 2025-12-31 | $54.19M | -5.6% |
| Pyxis Oncology, Inc. (PYXS) | 2025-12-31 | $15.42M | -20.8% |
| Eton Pharmaceuticals, Inc. (ETON) | 2025-12-31 | $25.94M | +73.7% |
| Relmada Therapeutics, Inc. (RLMD) | 2025-12-31 | $3.50M | -9.3% |
| Eupraxia Pharmaceuticals Inc. (EPRX) | 2025-12-31 | $80.56M | +143.4% |
| Journey Medical Corp (DERM) | 2025-12-31 | $24.09M | +18.6% |
| Arbutus Biopharma Corp (ABUS) | 2025-12-31 | $18.01M | -50.4% |
Compare DWTX, VTVT, STTK, PYXS side by side · Screen every company in Pharmaceutical Preparations ↗